Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism
- PMID: 16456813
- DOI: 10.1002/cncr.21697
Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism
Abstract
Background: To date, several mechanisms have been described by which malignant cells escape from the immune system. One of these is through the expression of FasL. The authors hypothesized that the Fas/FasL interaction enables cervical carcinoma cells to induce apoptosis of the cells of the immune system and thereby escape from them.
Methods: The authors tested the expression of FASL on the surface of cervical carcinoma tissues. Next, they stained the same cervical tissues with anti-human leukocyte common antigen and TUNEL to identify apoptotic cells. An in vitro functional assay was then done to test if the FASL expressed on the surface of cervical carcinoma cell lines was or was not responsible for inducing apoptosis in T-cells. Finally, they compared the expression of FASL on normal and dysplastic cervical tissues.
Results: Ninety-four percent of the cervical carcinoma tissues the authors tested expressed FasL and the majority of the apoptotic cells in the specimens were leukocytes with very few tumor cells. In the in vitro functional assay, only the Fasl expressing cell line and not the Fasl negative cell line was able to induce apoptosis of the Fas-expressing Jurkat cells. On examining the normal cervical tissues, the authors found that the expression of Fasl was confined to the basal cell layer with loss of expression observed in the suprabasal layers, which made it an immune privileged site. Conversely, there was persistent expression of FasL in the dysplastic layers in cervical dysplasia and squamous cell carcinoma specimens.
Conclusions: The findings of the current study support the authors' hypothesis that persistent expression of FasL plays a role in the ability of cervical carcinoma cells to escape from the immune system.
Similar articles
-
Fas-mediated pathway and apoptosis in normal cervix, cervical intraepithelial neoplasia and cervical squamous cancer.Oncol Rep. 2006 Aug;16(2):307-11. Oncol Rep. 2006. PMID: 16820908
-
Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study.Gynecol Oncol. 2005 Mar;96(3):705-13. doi: 10.1016/j.ygyno.2004.10.046. Gynecol Oncol. 2005. PMID: 15721415
-
FasL expression in colorectal carcinoma and its significance in immune escape of cancer.J Huazhong Univ Sci Technolog Med Sci. 2006;26(1):79-81. doi: 10.1007/BF02828044. J Huazhong Univ Sci Technolog Med Sci. 2006. PMID: 16711013
-
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.
-
Considering Fas ligand as a target for therapy.Expert Opin Ther Targets. 2005 Feb;9(1):119-34. doi: 10.1517/14728222.9.1.119. Expert Opin Ther Targets. 2005. PMID: 15757486 Review.
Cited by
-
Tim-3 expression in cervical cancer promotes tumor metastasis.PLoS One. 2013;8(1):e53834. doi: 10.1371/journal.pone.0053834. Epub 2013 Jan 15. PLoS One. 2013. Retraction in: PLoS One. 2024 Jul 25;19(7):e0308113. doi: 10.1371/journal.pone.0308113. PMID: 23335978 Free PMC article. Retracted.
-
Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression.Cancer Immunol Immunother. 2008 Mar;57(3):325-36. doi: 10.1007/s00262-007-0372-6. Epub 2007 Aug 1. Cancer Immunol Immunother. 2008. PMID: 17668204 Free PMC article.
-
Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy.Cancer Immunol Immunother. 2022 Jul;71(7):1597-1609. doi: 10.1007/s00262-021-03095-z. Epub 2021 Nov 3. Cancer Immunol Immunother. 2022. PMID: 34731284 Free PMC article.
-
Corticotropin-releasing hormone (CRH) is expressed in the human cervical carcinoma cells (HeLa) and upregulates the expression of Fas ligand.Tumour Biol. 2013 Feb;34(1):125-30. doi: 10.1007/s13277-012-0519-8. Epub 2012 Oct 18. Tumour Biol. 2013. PMID: 23076876
-
Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.Tumour Biol. 2015 Apr;36(4):2709-24. doi: 10.1007/s13277-014-2896-7. Epub 2014 Dec 4. Tumour Biol. 2015. PMID: 25472583
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous